Biocon Biologic (BBL), a subsidiary of Biocon announces to enter into a definitive agreement and acquire Viatris biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive cash consideration of about $2 billion on the closing of the transaction and up to $335 million as additional payments.
Read the original article here: https://www.biocon.com/biocon-biologics-to-acquire-viatris-biosimilars-assets-for-up-to-usd-3-335-billion-in-stock-and-cash/